Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Interventional
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The rate of grade 2 or greater adverse events related to study participation will be compared to historical controls matched for diagnosis and chemotherapy regimen.
Confirm the safety of the addition of plerixafor as a single dose or as a two-day dose commencing 2 hours before the high dose chemotherapy regimen prior to autologous stem cell transplantation.
2 hours before high dose chemotherapy
Yes
Andreas K Klein, MD
Principal Investigator
Tufts Medical Center
United States: Institutional Review Board
Plerixafor
NCT01610999
May 2013
May 2016
Name | Location |
---|---|
Tufts Medical Center | Boston, Massachusetts 02111 |